Clinical Trial: Initial dual-drug combination therapy with finerenone, dapagliflozin, or semaglutide in patients with type 2 Diabetes related chronic kidney disease (China)

Posted On: 2026-10-01

China, Oct. 1 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Initial dual-drug combination therapy with finerenone, dapagliflozin, or semaglutide in patients with type 2 Diabetes related chronic kidney disease'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600133684

Registration Time: 2026/09/30

Type: Interventional study

Primary Sponsor: The First Affiliated Hospital of Anhui Medical University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=343644

Published by HT Digital Content Services with permission from Health Daily Digest....

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

Clinical Trial: Initial dual-drug combination therapy with finerenone, dapagliflozin, or semaglutide in patients with type 2 Diabetes related chronic kidney disease (China)